Luciano Baronciani
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Luciano Baronciani has a total of 63 co-authors. Here are the top co-authors by number of shared publications:
- Flora Peyvandi
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy
10 shared publications - Omid Seidizadeh
Fondazione IRCCS Ca’Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy
6 shared publications - Maria Teresa Pagliari
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy
5 shared publications - Paola Colpani
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy
5 shared publications - Giovanna Cozzi
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy
4 shared publications - Alessandro Ciavarella
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy
2 shared publications
Latest Publications
- Open Access
- 18 September 2026
- Published by Elsevier in Research and Practice in Thrombosis and Haemostasis
- Vol. 10 (7) , 106971
A screening assay for type 2B von Willebrand factor variants using an enzyme-linked immunosorbent assay based on recombinant wild-type glycoprotein Ib and ristocetin
- 18 September 2026
- Published by Elsevier in Research and Practice in Thrombosis and Haemostasis
- Vol. 10 (7) , 106971
Open AccessA screening assay for type 2B von Willebrand factor variants using an enzyme-linked immunosorbent assay based on recombinant wild-type glycoprotein Ib and ristocetin
- Open Access
- 10 June 2026
- Published by Wiley in American Journal of Hematology
- Vol. 101 (9) , 2147-2156
Clinical and Laboratory Characterization of Acquired Von Willebrand Syndrome
Acquired von Willebrand Syndrome (AVWS) is a rare bleeding disorder characterized by quantitative or qualitative defects of von Willebrand factor (VWF) in patients without a personal or family history of bleeding. It is frequently associated with systemic diseases, particularly lymphoproliferative disorders (LPDs) and myeloproliferative neoplasms (MPNs). In this single‐center, retrospective cross‐sectional study, we included patients diagnosed with AVWS at the Angelo Bianchi Bonomi Hemophilia and Thrombosis Center between April 2014 and March 2025. Bleeding severity was assessed using the ISTH‐BAT score. Laboratory tests included FVIII:C, VWF:Ag, VWF:GPIbR, VWF:RCo, VWF:CB, VWFpp, and multimer analysis. Among 140 patients, 106 (76%) had MPNs and 26 (19%) LPDs. At least one bleeding symptom was observed in 70% of patients, with clinically significant bleeding occurring in 24% of the cohort. Clinically relevant bleeding (mainly mucocutaneous and gastrointestinal) was more frequent and severe in LPDs (58%) than in MPNs (13%). LPDs showed severe VWF functional defects, marked HMWM loss, and elevated VWFpp/VWF:Ag ratios (median 6.7), consistent with accelerated clearance. MPNs displayed mild HMWM reduction, normal clearance (median VWFpp/VWF:Ag ratio 1.0), and an inverse correlation between platelet count and the degree of HMWM depletion (ρ = −0.48, p < 0.001). Bleeding severity correlated inversely with VWF:GPIbR in LPDs (ρ = −0.50, p = 0.02) and with VWF:RCo in MPNs. Anti‐VWF antibodies were found in 30% of tested LPDs or autoimmune cases. The two main phenotypes presented in AVWS were immune‐mediated in LPDs and platelet‐mediated in MPNs. Understanding the underlying mechanism is crucial for accurate diagnosis and targeted treatment to reduce bleeding risk and improve outcomes.
- 10 June 2026
- Published by Wiley in American Journal of Hematology
- Vol. 101 (9) , 2147-2156
Open AccessClinical and Laboratory Characterization of Acquired Von Willebrand Syndrome
Acquired von Willebrand Syndrome (AVWS) is a rare bleeding disorder characterized by quantitative or qualitative defects of von Willebrand factor (VWF) in patients without a personal or family history of bleeding. It is frequently associated with systemic diseases, particularly lymphoproliferative disorders (LPDs) and myeloproliferative neoplasms (MPNs). In this single‐center, retrospective cross‐sectional study, we included patients diagnosed with AVWS at the Angelo Bianchi Bonomi Hemophilia and Thrombosis Center between April 2014 and March 2025. Bleeding severity was assessed using the ISTH‐BAT score. Laboratory tests included FVIII:C, VWF:Ag, VWF:GPIbR, VWF:RCo, VWF:CB, VWFpp, and multimer analysis. Among 140 patients, 106 (76%) had MPNs and 26 (19%) LPDs. At least one bleeding symptom was observed in 70% of patients, with clinically significant bleeding occurring in 24% of the cohort. Clinically relevant bleeding (mainly mucocutaneous and gastrointestinal) was more frequent and severe in LPDs (58%) than in MPNs (13%). LPDs showed severe VWF functional defects, marked HMWM loss, and elevated VWFpp/VWF:Ag ratios (median 6.7), consistent with accelerated clearance. MPNs displayed mild HMWM reduction, normal clearance (median VWFpp/VWF:Ag ratio 1.0), and an inverse correlation between platelet count and the degree of HMWM depletion (ρ = −0.48, p < 0.001). Bleeding severity correlated inversely with VWF:GPIbR in LPDs (ρ = −0.50, p = 0.02) and with VWF:RCo in MPNs. Anti‐VWF antibodies were found in 30% of tested LPDs or autoimmune cases. The two main phenotypes presented in AVWS were immune‐mediated in LPDs and platelet‐mediated in MPNs. Understanding the underlying mechanism is crucial for accurate diagnosis and targeted treatment to reduce bleeding risk and improve outcomes.
- 26 December 2025
- Published by Georg Thieme Verlag KG in Seminars in Thrombosis and Hemostasis
- Vol. 52 (06) , 618-627
Von Willebrand Disease Type 2A: An Update
Dysfunctional or quantitatively deficient von Willebrand factor (VWF) underlies von Willebrand disease (VWD), the most common inherited bleeding disorder. Type 2A VWD is a qualitative defect marked by impaired VWF-dependent platelet adhesion, typically reflected in disproportionately reduced ratios of platelet-dependent VWF activity to antigen (VWF activity/VWF:Ag) and collagen binding to antigen (VWF:CB/VWF:Ag). This phenotype results from a selective reduction or lack of high- and intermediate-molecular-weight multimers, which are essential for effective hemostasis under high shear stress. The lack of multimer arises from impaired multimer assembly and/or increased proteolytic cleavage of VWF by ADAMTS13. Clinically, type 2A tends to present with greater severity than other type 2 variants, manifesting as mucocutaneous bleeding, often including heavy menstrual bleeding, epistaxis, post-surgical bleeding and gastrointestinal hemorrhage from angiodysplasia. Diagnosis relies on functional assays and VWF multimer analysis, supported by genetic testing that identifies subtype-specific mutations affecting VWF multimeric structure and therefore its function. Type 2A is typically inherited in an autosomal dominant manner, with rare exceptions of autosomal recessive inheritance. Structural and molecular studies are continuing to elucidate how domain-specific variants disrupt multimeric structure and thus interactions with its ligands. Management is guided by bleeding severity and includes desmopressin (following responsiveness testing) and VWF replacement therapy. This review provides an in-depth update on type 2A VWD, covering its epidemiology, pathophysiology across distinct subtypes, clinical manifestations, diagnostic approach, molecular and structural insights, and current therapeutic strategies.
- 26 December 2025
- Published by Georg Thieme Verlag KG in Seminars in Thrombosis and Hemostasis
- Vol. 52 (06) , 618-627
Von Willebrand Disease Type 2A: An Update
Dysfunctional or quantitatively deficient von Willebrand factor (VWF) underlies von Willebrand disease (VWD), the most common inherited bleeding disorder. Type 2A VWD is a qualitative defect marked by impaired VWF-dependent platelet adhesion, typically reflected in disproportionately reduced ratios of platelet-dependent VWF activity to antigen (VWF activity/VWF:Ag) and collagen binding to antigen (VWF:CB/VWF:Ag). This phenotype results from a selective reduction or lack of high- and intermediate-molecular-weight multimers, which are essential for effective hemostasis under high shear stress. The lack of multimer arises from impaired multimer assembly and/or increased proteolytic cleavage of VWF by ADAMTS13. Clinically, type 2A tends to present with greater severity than other type 2 variants, manifesting as mucocutaneous bleeding, often including heavy menstrual bleeding, epistaxis, post-surgical bleeding and gastrointestinal hemorrhage from angiodysplasia. Diagnosis relies on functional assays and VWF multimer analysis, supported by genetic testing that identifies subtype-specific mutations affecting VWF multimeric structure and therefore its function. Type 2A is typically inherited in an autosomal dominant manner, with rare exceptions of autosomal recessive inheritance. Structural and molecular studies are continuing to elucidate how domain-specific variants disrupt multimeric structure and thus interactions with its ligands. Management is guided by bleeding severity and includes desmopressin (following responsiveness testing) and VWF replacement therapy. This review provides an in-depth update on type 2A VWD, covering its epidemiology, pathophysiology across distinct subtypes, clinical manifestations, diagnostic approach, molecular and structural insights, and current therapeutic strategies.
- 5 September 2025
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 23 (12) , 3845-3857
Evaluation of different platelet-dependent von Willebrand factor activity assays to assess the in vivo inhibitory effect of caplacizumab on the von Willebrand factor–platelet interaction
- 5 September 2025
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 23 (12) , 3845-3857
Evaluation of different platelet-dependent von Willebrand factor activity assays to assess the in vivo inhibitory effect of caplacizumab on the von Willebrand factor–platelet interaction
- Open Access
- 18 January 2025
- Published by Elsevier in Research and Practice in Thrombosis and Haemostasis
- Vol. 9 (1) , 102686
Challenges and considerations of genetic testing in von Willebrand disease
- 18 January 2025
- Published by Elsevier in Research and Practice in Thrombosis and Haemostasis
- Vol. 9 (1) , 102686
Open AccessChallenges and considerations of genetic testing in von Willebrand disease
- Top Cited Papers
- 25 July 2024
- Published by Springer Nature in Nature Reviews Disease Primers
- Vol. 10 (1) , 1-18
von Willebrand disease
Von Willebrand disease (VWD) is the most common inherited bleeding disorder. The disorder is characterized by excessive mucocutaneous bleeding. The most common bleeding manifestations of this condition include nosebleeds, bruising, bleeding from minor wounds, menorrhagia or postpartum bleeding in women as well as bleeding after surgery. Other less frequent symptoms include gastrointestinal bleeding, haematomas or haemarthroses. VWD pathophysiology is complex and results from defects in von Willebrand factor (VWF) glycoprotein. Quantitative deficiencies are responsible for type 1 VWD with a partial decrease of VWF and type 3 with the complete absence of VWF. Qualitative abnormalities cause type 2 VWD, being further divided into types 2A, 2B, 2M and 2N. Although common, VWD is at risk of misdiagnosis, overdiagnosis and underdiagnosis owing to several factors, including complex diagnosis, variability of bleeding symptoms, presence of external variables (blood groups and other physiological modifiers such as exercise, thyroid hormones, oestrogens, and ageing), and lack of disease awareness among non-specialist health-care providers. Establishing the correct VWD diagnosis requires an array of specialized phenotypic assays and/or molecular genetic testing of the VWF gene. The management of bleeding includes increasing endogenous VWF levels with desmopressin or infusion of exogenous VWF concentrates (plasma-derived or recombinant). Fibrinolytic inhibitors, topical haemostatic agents and hormonal therapies are used as effective adjunctive measures.
- 25 July 2024
- Published by Springer Nature in Nature Reviews Disease Primers
- Vol. 10 (1) , 1-18
Top Cited Papersvon Willebrand disease
Von Willebrand disease (VWD) is the most common inherited bleeding disorder. The disorder is characterized by excessive mucocutaneous bleeding. The most common bleeding manifestations of this condition include nosebleeds, bruising, bleeding from minor wounds, menorrhagia or postpartum bleeding in women as well as bleeding after surgery. Other less frequent symptoms include gastrointestinal bleeding, haematomas or haemarthroses. VWD pathophysiology is complex and results from defects in von Willebrand factor (VWF) glycoprotein. Quantitative deficiencies are responsible for type 1 VWD with a partial decrease of VWF and type 3 with the complete absence of VWF. Qualitative abnormalities cause type 2 VWD, being further divided into types 2A, 2B, 2M and 2N. Although common, VWD is at risk of misdiagnosis, overdiagnosis and underdiagnosis owing to several factors, including complex diagnosis, variability of bleeding symptoms, presence of external variables (blood groups and other physiological modifiers such as exercise, thyroid hormones, oestrogens, and ageing), and lack of disease awareness among non-specialist health-care providers. Establishing the correct VWD diagnosis requires an array of specialized phenotypic assays and/or molecular genetic testing of the VWF gene. The management of bleeding includes increasing endogenous VWF levels with desmopressin or infusion of exogenous VWF concentrates (plasma-derived or recombinant). Fibrinolytic inhibitors, topical haemostatic agents and hormonal therapies are used as effective adjunctive measures.
- 16 May 2024
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 22 (8) , 2115-2128
Application of genetic testing for the diagnosis of von Willebrand disease
- 16 May 2024
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 22 (8) , 2115-2128
Application of genetic testing for the diagnosis of von Willebrand disease
- Open Access
- 25 August 2023
- Published by Elsevier in Research and Practice in Thrombosis and Haemostasis
- Vol. 7 (6) , 102174
Reply to “Comment on: A comparative study in type 2 von Willebrand disease patients using four different platelet-dependent von Willebrand factor assays”
- 25 August 2023
- Published by Elsevier in Research and Practice in Thrombosis and Haemostasis
- Vol. 7 (6) , 102174
Open AccessReply to “Comment on: A comparative study in type 2 von Willebrand disease patients using four different platelet-dependent von Willebrand factor assays”
- Open Access
- 30 March 2023
- Published by Elsevier in Research and Practice in Thrombosis and Haemostasis
- Vol. 7 (3) , 100139
A comparative study in patients with type 2 von Willebrand disease using 4 different platelet-dependent von Willebrand factor assays
- 30 March 2023
- Published by Elsevier in Research and Practice in Thrombosis and Haemostasis
- Vol. 7 (3) , 100139
Open AccessA comparative study in patients with type 2 von Willebrand disease using 4 different platelet-dependent von Willebrand factor assays
- 7 May 2020
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 18 (9) , 2145-2154
Bleeding symptoms in patients diagnosed as type 3 von Willebrand disease: Results from 3WINTERS‐IPS, an international and collaborative cross‐sectional study
- 7 May 2020
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 18 (9) , 2145-2154
Bleeding symptoms in patients diagnosed as type 3 von Willebrand disease: Results from 3WINTERS‐IPS, an international and collaborative cross‐sectional study